Quince Therapeutics, Inc. (IRLA) Net income 2018–2025
Quince Therapeutics, Inc. (IRLA) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$84.0MFY2025 · since FY2018: -$12.5M → -$84.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$84.0M | -47.8% |
| FY2024 | -$56.8M | -81.1% |
| FY2023 | -$31.4M | +39.2% |
| FY2022 | -$51.7M | +42.6% |
| FY2021 | -$89.9M | -17.0% |
| FY2020 | -$76.8M | -107.8% |
| FY2019 | -$37.0M | -196.4% |
| FY2018 | -$12.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IRLA financial trends
IRLA RevenueIRLA Net marginIRLA Gross profitIRLA Gross marginIRLA Operating incomeIRLA Operating marginIRLA Operating cash flowIRLA Free cash flowIRLA Capital expendituresIRLA Return on equityIRLA Stock buybacksIRLA Dividends paidIRLA Total assetsIRLA Total liabilitiesIRLA Shareholders’ equityIRLA overview →